skip to main content

AB0509 Comparative effectiveness of tocilizumab (TCZ) and rituximab (RTM) using different disease activity indices (DAS 28, SDAI and CDAI) in patients with rheumatoid arthritis (RA)

Avdeeva, A.S. ; Alexandrova, E.N. ; Panasyuk, E.Y. ; Lukina, G.V. ; Nasonov, E.L.

Annals of the Rheumatic Diseases June 2013, Vol.71(Suppl 3), p.667 [Periódico revisado por pares]

BMJ Publishing Group Ltd and European League Against Rheumatism

Texto completo disponível

Ver todas as versões
Citações Citado por
  • Título:
    AB0509 Comparative effectiveness of tocilizumab (TCZ) and rituximab (RTM) using different disease activity indices (DAS 28, SDAI and CDAI) in patients with rheumatoid arthritis (RA)
  • Autor: Avdeeva, A.S. ; Alexandrova, E.N. ; Panasyuk, E.Y. ; Lukina, G.V. ; Nasonov, E.L.
  • É parte de: Annals of the Rheumatic Diseases June 2013, Vol.71(Suppl 3), p.667
  • Descrição: Humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody (TCZ) and chimeric monoclonal antibody against CD 20 positive B cells (RTM) are effective and safe preparations for the treatment of RA. Taking into account the different mechanisms of action, time of coming effect, influence on a acute -phase reactants, it is interesting to compare the effectiveness of treatment TCZ and RTM using different composite disease activity indices (DAS 28, SDAI and CDAI) and the new criteria remission ACR/EULAR 2011.
  • Editor: BMJ Publishing Group Ltd and European League Against Rheumatism
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.